Physician profile
David Brian Macisaac
NPI 1437181336
$6,342.92
in general payments reported to CMS, 2019-2025
24 companies · $214 in 2025
The $214 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,043 · 2020: $805 · 2021: $1,855 · 2022: $1,197 · 2023: $955 · 2024: $275 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,443.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $2,810.70 | 2019-2023 | Injectafer |
| Novo Nordisk INC | $1,359.51 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $488.49 | 2021-2025 | |
| Lilly USA, LLC | $213.26 | 2019-2025 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $208.06 | 2019-2021 | |
| Welch Allyn | $147.04 | 2021 | |
| Baxter Healthcare | $147.04 | 2022 | |
| Pfizer INC. | $146.82 | 2019-2023 | |
| Kestra Medical Technology Services, INC. | $143.77 | 2023 | Assure Wcd |
| Amgen INC. | $136.29 | 2019-2025 | Evenity, Prolia, Prolia |
| Astrazeneca Pharmaceuticals LP | $126.45 | 2019-2025 | Airsupra, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $119.10 | 2021-2023 | Trintellix |
| Optinose US, INC. | $50.94 | 2020-2021 | |
| Glaxosmithkline, LLC. | $42.99 | 2022-2024 | Trelegy Ellipta |
| Lundbeck LLC | $41.95 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $29.69 | 2023 | Seglentis, Livalo |
| Amarin Pharma, INC. | $23.29 | 2021 | |
| Exact Sciences Corporation | $22.96 | 2025 | The Cologuard Plus Collection Kit |
| Ardelyx, INC. | $19.51 | 2023 | Ibsrela |
| Sanofi Pasteur INC. | $16.62 | 2019 | |
| Biogen, INC. | $13.00 | 2021 | |
| Vivus LLC | $12.51 | 2019 | |
| Allergan, INC. | $11.64 | 2020 | |
| Eisai INC. | $11.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Macisaac listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.